Herpes zoster vaccination efficacy in the long-term care facility population: a qualitative systematic review

References

• Harpaz R, Ortaga-Sanchez IR, Seward JF. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2008;57:1–30.
   PubMedGoogle Scholar
• Facts About Chickenpox For Adults [Internet]. Adultvaccination.Org; 2019 [cited 2019 Jan 31]. Available from: http://www.adultvaccination.org/vpd/chickenpox/facts.html
   Google Scholar
• Drinka PJ. How should nursing homes use vaccine to prevent zoster? J Am Med Dir Assoc. 2007;8:419–420.
   PubMed Web of Science ®Google Scholar
• Bader MS. Immunization for the elderly. Am J Med Sci. 2007;334:481–486.
   PubMed Web of Science ®Google Scholar
• Schafer KM, Reidt S. Herpes zoster vaccine in the long-term care setting: a clinical and logistical conundrum. Consult Pharm. 2016;31:33–37.
   PubMedGoogle Scholar
• Brisson M, Pellissier JM, Camden S, et al. The potential costeffectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4:238–245.
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284.
   PubMed Web of Science ®Google Scholar
• Lelic A, Verschoor CP, Lau VWC, et al. Immunogenicity of varicella vaccine and immunologic predictors of response in a cohort of elderly nursing home residents. J Infect Dis. 2016;214:1905–1910.
   PubMed Web of Science ®Google Scholar
• Boivin G, Jovey R, Elliott CT, et al. Management and prevention of herpes zoster: a Canadian perspective. Can J Infect Dis Med Microbiol. 2010;21:45–52.
   PubMed Web of Science ®Google Scholar
• Shingles | Signs And Symptoms | Herpes Zoster | CDC [Internet]. Cdc.Gov; 2019 [cited 2018 Dec 25]. Available from: https://www.cdc.gov/shingles/about/symptoms.html.
   Google Scholar
• Kowalsky DS, Wolfson AB. Corticosteroids for preventing post herpetic neuralgia after herpes zoster infection. Acad Emer Med. 2018;25(11):1189–1311.
   Google Scholar
• Bennett GJ, Watson CP. Herpes zoster and postherpetic neuralgia: past, present and future. Pain Res Manag. 2009;14:275–282.
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ, et al. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833–e004833.
   PubMed Web of Science ®Google Scholar
• Herpes Z. (Shingles) Vaccine: Canadian Immunization Guide [Internet]. Canada: Government of Canada [cited 2018 Sep 30]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadianimmunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html
   Google Scholar
• Gabutti G, Valente N, Kuhdari P, et al. Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine. J Med Microbiol. 2016;65:1363–1369.
   PubMed Web of Science ®Google Scholar
• Shingles Prevention Study – Full Text View – Clinicaltrials.Gov [Internet]. Clinicaltrials.Gov; 2019 [cited 2019 Jan 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT00007501.
   Google Scholar
• Simberkoff MS. Safety of herpes zoster vaccine in the shingles prevention study. Ann Intern Med. 2010;152:545.
   PubMed Web of Science ®Google Scholar
• Young L. Zoster vaccine live for the prevention of shingles in the elderly patient. CIA. 2008;3:241–250.
   Google Scholar
• Canada, Public. Provincial And Territorial Routine Vaccination Programs For Healthy, Previously Immunized Adults – Canada.Ca. Canada.Ca; 2019 [cited 2019 Jan 19]. Available from: https://www.canada.ca/en/public-health/services/provincial-territorial-immunization-information/routine-vaccination-healthy-previously-immunized-adult.html
   Google Scholar
• Nace DA, Drinka PJ, Crnich CJ. Herpes zoster vaccine in nursing facility residents: safety questions remain. Ann Intern Med. 2010;153:210–211.
   PubMed Web of Science ®Google Scholar
• Joesoef RM, Harpaz R, Leung J, et al. Chronic medical conditions as risk factors for herpes zoster. Mayo Clin Proc. 2012;87:961–967.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65 years and older. Clin Infect Dis. 2017;64:785–793.
   PubMed Web of Science ®Google Scholar
• Langan SM, Thomas SL, Smeeth L, et al. Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:2095–2098.
   PubMed Web of Science ®Google Scholar
• Marin M, Yawn BP, Hales CM, et al. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother. 2015;11:1157–1164.
   PubMed Web of Science ®Google Scholar
• Russell AF, Parrino J, Fisher CL Jr, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015;33:3129–3134.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Luo Y, Tartof S, et al. Herpes zoster vaccination and risk of herpes zoster among demential population aged 60 years and older. Alzheimers Dement. 2015;11:897.
   Google Scholar
• Alexandridou M, Bollaerts K. Zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in elderly in the UK. Value Health. 2017;20:A780.
   Web of Science ®Google Scholar
• Kovac M, Lal H, Cunningham AL, et al. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018;36:1537–1541.
   PubMed Web of Science ®Google Scholar
• Baxter R, Bartlett J, Fireman B, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2018;187:161–169.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Popmihajlov Z, Schmader KE, et al. Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine. J Infect Dis. 2018;219:335–338.
   Web of Science ®Google Scholar
• Rockwood K, Mogilner A, Mitnitski A. Changes with age in the distribution of a frailty index. Mech Ageing Dev. 2004;125:517–519.
   PubMed Web of Science ®Google Scholar
• Tabue-Teguo M, Kelaiditi E, Demougeot L, et al. Frailty index and mortality in nursing home residents in France: results from the INCUR study. J Am Med Dir Assoc. 2015;16:603–606.
   PubMed Web of Science ®Google Scholar
• Patel MS, Gebremariam A, Davis MM. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect Control Hosp Epidemiol. 2008;29:1157–1163.
   PubMed Web of Science ®Google Scholar
• Lin YH, Huang LM, Chang IS, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28:1217–1220.
   PubMed Web of Science ®Google Scholar
• Panatto D, Bragazzi NL, Rizzitelli E, et al. Evaluation of the economic burden of herpes zoster (HZ) infection: a systematic literature review. Hum Vaccin Immunother. 2015;11:245–262.
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Marra CA, Galanis E, et al. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27:991–1004.
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44:1280–1288.
   PubMed Web of Science ®Google Scholar
• Langan SM, Thomas SL, Smeeth L, et al. Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31(12):2095–2098.
   PubMed Web of Science ®Google Scholar
• Herpes Z. (Shingles) Immunisation Programme 2017 To 2018: Evaluation Report. 2019 [cited 2019 Jan 31]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/758888/hpr4218_shngls_vc.pdf
   Google Scholar
• Vaccination Des Adultes Contre Le Zona Avec Le Vaccin Zostavax. Hcsp.Fr; 2019 [cited 2019 Jan 31]. Available from: https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=390
   Google Scholar
• Ncirs.Org.Au; 2019 [cited 2019 Jan 31]. Available from: http://www.ncirs.org.au/sites/default/files/2018-12/Zoster-history-Dec-2018.pdf
   Google Scholar
• Ncirs.Org.Au; 2019 [cited 2019 Jan 31]. Available from: http://www.ncirs.org.au/sites/default/files/2018-12/zoster-vaccine-fact-sheet.pdf
   Google Scholar
• Zostavax. Immunisation Advisory Centre; 2019 [cited 2019 Jan 30]. Available from: http://www.immune.org.nz/vaccines/available-vaccines/zostavax
   Google Scholar
• World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014 – recommendations. Vaccine. 2016;34:198–199.
   PubMed Web of Science ®Google Scholar
• Lu P-J, O’Halloran A, Williams WW, et al. National and state-specific shingles vaccination among adults aged ≥60 years. Am J Prev Med. 2017;52:362–372.
   PubMed Web of Science ®Google Scholar
• National Vaccine Storage and Handling Guidelines for Immunization Providers 2015 [Internet]. Canada: Government of Canada [cited 2018 Sep 30]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/nationalvaccine-storage-handling-guidelines-immunization-providers-2015.html
   Google Scholar
• Hata A, Inoue F, Hamamoto Y, et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, doubleblind, placebo-controlled trial. Diabet Med. 2016;33:1094–1101.
   PubMed Web of Science ®Google Scholar
• Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella Zoster virus-specific immune responses to a herpes Zoster Vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis. 2013;56(8):1085–1093.
   PubMed Web of Science ®Google Scholar